Medical/Pharmaceuticals
Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE
ROCKVILLE, Md. and SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of China ...
2023-10-13 08:22
2514
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy
.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone1 .. Phase 3 results expected in 2025 .. Exclusive license for AU, NZ, Singapore, Mal...
2023-10-13 03:00
4149
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival
SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in th...
2023-10-12 20:50
2588
Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)
HONG KONG, Oct. 12, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") announced that the results of the multicenter, open-label Phase Ib/II clinical trial (COMPASSION-03/AK104-201) for cadonilimab (PD-1/CTLA-4 bispecific antibody), the globally first bispecific IO drug used to treat advanced s...
2023-10-12 20:00
2462
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192
* HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinson's Disease in collaboration with NurrOn Pharmaceuticals. * The Phase 1 Study evaluates the safety, tolerability, and pharmacokinetics of ...
2023-10-12 19:00
2542
MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate
SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- MediLink Therapeutics ("MediLink"), announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therap...
2023-10-12 19:00
2617
Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress
SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has unveiled its phase III clinica...
2023-10-12 18:49
2240
So-Young Announces Board Change
BEIJING, Oct. 12, 2023 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that Mr.Min Yu, Mr. Xuejian ...
2023-10-12 18:00
4347
MicuRx announces poster presentation and participation in ID Week 2023 Conference
FOSTER CITY, Calif., Oct. 11, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, announces that a poster on our preclinical product, MRX-6038, will be p...
2023-10-11 23:33
2650
SINGAPORE AND JAPAN CLINICIAN-SCIENTISTS COLLABORATE ON GROUNDBREAKING TELESURGERY TRIAL SPANNING OVER 5,000KM
This preclinical trial surgery involves clinician-scientists in NUS Medicine and theNational University Hospital in partnership with Fujita Health University SINGAPORE, Oct. 11, 2023 /PRNewswire/ -- Singapore's National University Hospital (NUH) and the Yong Loo Lin School of Medicine at theNatio...
2023-10-11 22:13
3950
Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
SUZHOU, China, Oct. 11, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional appr...
2023-10-11 17:20
2782
TaiGen Enters Exclusive License Agreement with YSP
TAIPEI, Oct. 10, 2023 /PRNewswire/ -- TaiGen Biopharmaceuticals Holdings Ltd. ("TaiGen") announces that TaiGen Biotechnology, a subsidiary company of TaiGen, have signed an exclusive licensing agreement with Y.S.P. Industries (M) Sdn. Bhd. to develop and commercialize TaiGen's new drug inMalaysia...
2023-10-11 11:24
3084
GC Biopharma Shares its Successful HR System Transformation at SAP Success Connect 2023
YONGIN, South Korea, Oct. 10, 2023 /PRNewswire/ -- GC Biopharma Corp. announced today that it has presented the successful adoption of SAP SuccessFactor Work Zone, which is a cloud-based HR solution by SAP, at the SAP Success Connect 2023 held onOctober 3rd in Las Vegas. SAP Success Connect is...
2023-10-11 08:49
2495
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
- Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet reached - Patent rights secured for TJ-L14B/ABL503 in Eurasia until 2039 ROCKVILLE, ...
2023-10-10 20:00
2191
GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
SHANGHAI, Oct. 10, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first subject was dosed in a phase Ib/II trial of GFH009 (a highly selective CDK9 inhibitor) treating relapsed/r...
2023-10-10 19:00
1988
CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region
SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC (Hikma), today announced the signing of distribution and license agreement for oregovomab in theMiddle East andNorth Africa (MENA) region. "We are thrilled to partner with Hi...
2023-10-10 12:00
2500
Dr. Ming H. Wu, Former Senior Vice President of Engineering at Edwards Lifesciences, Joins Medeologix as Board Member and Advisor
NEW TAIPEI CITY, Taiwan, Oct. 9, 2023 /PRNewswire/ -- Medeologix, a global
medical device contract development and manufacturing company known for its
one-stop shop service with engineering excellence, is pleased to announce that
Dr.Ming H. Wu has joined as a board member and advisor.
2023-10-09 23:00
2579
TransThera announces two oral presentations of tinengotinib clinical data at 2023 ESMO and SABCS annual meetings
NANJING, China, Oct. 9, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announces to deliver two oral presentations of tinengotinib clinical data in cholangiocarcinoma (CCA) at...
2023-10-09 21:00
2349
bioSeedin Biopharma Developer Innovation Conference Held to Accelerate Global Pharmaceutical Innovation and Collaboration
BOSTON, Oct. 9, 2023 /PRNewswire/ -- Recently, the fifth Biopharma Developer Innovation Conference (BDIC) & 2023 bioSeedin Annual Meeting was successfully held inShanghai, China. This conference was hosted by bioSeedin and co-organized by ACROBiosystems (SZ.301080) to promote technical exchanges ...
2023-10-09 20:00
2447
Kexing Biopharm Holds China-MENA & South Asia Pharmaceutical Cooperation High-end Forum, Aiming at Foreign Emerging Markets
SHENZHEN, China, Oct. 9, 2023 /PRNewswire/ -- The 2023 China-MENA & South Asia Pharmaceutical Cooperation High-end Forum and Kexing Biopharm's Series of Globalization Activities were successfully held recently. MENA and South Asia are recognized as pivotal regions for Kexing Biopharm's overseas ...
2023-10-09 19:09
2691
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 290 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
8629
QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration
2026-09-12 09:00
7947
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7041
